Navigation Links
Pharmasset Reports Fiscal First Quarter 2011 Financial Results
Date:2/7/2011

al purine nucleotide analog, PSI-661, in advanced preclinical development.

Pegasys(R) and Copegus(R) are registered trademarks of Roche. ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice +1 (609) 613-4181 Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates,  the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.

PHARMASSET, INC.CONDENSED STATEMENTS OF OPERATIONS(UNAUDITED)(in thousands, except share and per share amounts)Three Months EndedDecember 31,20102009Revenues

$
247$
269COSTS AND EXPENSES:  Research and development

18,7689,197  General and administrative

5,0764,239Total costs and expenses

23,84413,436Operating loss

<
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015 BioCorRx, ... Santa Ana, California is a healthcare ... for which is estimated at $22 billion in the U.S. ... the use of FDA-approved Naltrexone in a specially compounded form ... Australia and New Zealand ...
(Date:3/27/2015)... March 27, 2015 Across the global healthcare ... challenges in clinical development, market education, and regulatory compliance. ... Medical Affairs function is expected to increase in prominence ... According to research by benchmarking firm, Best ... group dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... 2015  The quality function within the medical device ... quality standards at every stage of the product life ... also have the challenge of balancing quality and safety ... don,t effectively balance these priorities risk funding and staffing ... and regulatory scrutiny. For the third consecutive ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2
... Clinical trials in which participants are randomly assigned to different ... conducted correctly, it,s widely accepted by the research community that ... But researchers at the University of Michigan hope to ... patients by investigating the impact of a class of innovative ...
... CRY ), an implantable biological medical device ... BioGlue Surgical Adhesive has received Shonin approval from the ... use in the repair of aortic dissections. ... in Japan for use in this subset of cardiac ...
Cached Medicine Technology:U-M Receives NIH, FDA Grant To Study Adaptive Clinical Trial Design 2CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 2CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 3CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 4CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 5
(Date:3/28/2015)... AZ (PRWEB) March 28, 2015 Coffee could ... also help protect you from gum disease, researchers have found. ... against gum disease. , Coffee contains antioxidants. Antioxidants fight gum ... the question researchers at Boston Univ. Henry M. Goldman School ... in the August 2014 issue of the Journal of Periodontology. ...
(Date:3/28/2015)... March 28, 2015 Could genetic code ... new study by researchers at the Harvard ... with the support of the Coffee and Caffeine Genetics ... Psychiatry this past fall, the study—one of several recent ... genomic data from more than 120,000 regular coffee drinkers ...
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part ... the latest and coolest applications on the market for ... NewsWatch and technology expert, conducted the app review and ... runner game with knights, nature, and peasants. , ... according to Eurogamer. The popularity of these games grew ...
(Date:3/28/2015)... Take a bite of warm, gooey pepperoni ... tumble into the stomach, ready to break down your ... these acids run amok, triggering a burning sensation in ... than 60 million Americans have heartburn at least once ... and how it can be stopped. , Heartburn or ...
(Date:3/28/2015)... 28, 2015 With more than ... fields of osteoporosis, osteoarthritis and musculoskeletal diseases gathered ... may be the first time in the 17-year ... that the hot-button topic is an emerging non-pharmaceutical ... well-accepted scientific principles of Wolff’s law, osteogenic loading ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2
... BeneChill, Inc. ( www.benechill.com ) today announced the ... study. This randomized study will determine whether intra-nasal ... patient resuscitation and survival rates.The PRINCE study is ... Europe. The company received CE marking for the ...
... manufacturer of,GUM(R) and Butler(R) brand products and a leader ... worldwide, is putting its support,behind the American Dental Association,s ... health. , Each February since ... to raise awareness about the importance of oral health. ...
... most symptoms fade within 6 weeks, experts say , , ... physical therapy and anti-inflammatory drugs is the most effective ... degenerative disc disease, according to a review of published ... 90 percent of people with low back pain, symptoms ...
... part in regular physical activity have a better quality ... issue of the journal Cancer Epidemiology Biomarkers and ... more physically active report better mood, more vigor, and ... take-home message is that early-stage lung cancer survivors may ...
... ANN ARBOR, Mich. One-fifth of women who should ... potentially lifesaving treatment, according to a new study from ... , The study looked at 396 women who were ... found that 19 percent of women who fell clearly ...
... Vitamin(R) has launched the web site for Keep ,Em ... that gives pregnant women the greatest opportunity to carry ... information and offering online community support. , ... Cookin, with one very specific goal in mind --- ...
Cached Medicine News:Health News:BeneChill Launches European Study of Intra-Arrest Cooling 2Health News:Sunstar to Support ADA's 60th Annual National Children's Dental Health Month 2Health News:Sunstar to Support ADA's 60th Annual National Children's Dental Health Month 3Health News:Therapy, Meds Best for Lumbar Low Back Pain 2Health News:Regular physical activity linked to better quality of life in early-stage lung cancer survivors 2Health News:19 percent of breast cancer patients don’t receive recommended radiation after mastectomy 2Health News:Vitamin Launches Online Face for Keep 'Em Cookin' 2
Benchtop UV Incubator is designed to provide precise temperature control and uniformity throughout the chamber. Decontaminate chamber between experiments with built-in shortwave UV....
Inquire...
Inquire...
Inquire...
Medicine Products: